Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 74/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results67% success

Data Visualizations

Phase Distribution

2Total

P 2 (2)

Trial Status

Completed2

Recruiting1

Terminated1

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials

NCT04924712Recruiting

INS, B Cells and Microbiota

NCT03536754Phase 2Completed

A Study of CCX140-B in Subjects With FSGS

NCT06766786Completed

Magnesium Supplementation in Simultaneous Pancreas-Kidney Transplantation

NCT04950114Phase 2Terminated

An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

Showing all 4 trials

Glomerulosclerosis